Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K report on January 31, 2018, announcing its financial results for the fourth quarter and full year ended December 31, 2017. The primary purpose of this filing is to incorporate by reference the press release detailing these results, which was issued concurrently. Investors should refer to the press release (Exhibit 99.1) for the comprehensive financial performance data, including revenue, earnings, and any forward-looking statements or guidance provided by the company.
Key Highlights
- 1Vertex Pharmaceuticals reported its consolidated financial results for the three and twelve months ended December 31, 2017.
- 2The announcement was made via a press release issued on January 31, 2018.
- 3The press release detailing the financial results is attached as Exhibit 99.1 to the 8-K filing.
- 4This filing primarily serves to formally include the press release in the company's SEC filings.
- 5Investors are directed to the press release for specific financial performance details and operational updates.
- 6The information presented in the press release is furnished and not deemed 'filed' for certain liability purposes under the Securities Exchange Act of 1934.